07 January 2019
("Physiomics") or ("the Company")
Physiomics to participate in Biotech Showcase partnering conference
Physiomics plc (AIM: PYC), is pleased to announce that it will be attending the Biotech Showcase partnering conference in San Francisco from 7-9 January 2019 during the JP Morgan Healthcare Conference week. During this week, many of the world's most successful biotech and pharmaceutical companies are present in San Francisco to meet with prospective clients and partners. Over three thousand attendees are expected to participate in over seven thousand organised 1-1 meetings. Physiomics has confirmed meetings with oncology companies from around the world interested in finding out more about our Virtual Tumour platform and how it can enhance their drug discovery and development programs.
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by over 60 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.
For more information please visit:
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(END) Dow Jones Newswires
January 07, 2019 02:00 ET (07:00 GMT)